VFA
AKCA

Virtus Fund Advisers’s Akcea Therapeutics Inc AKCA Stock Holding History

Virtus Fund Advisers’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$314K Buy
+18,071
New +$354K ﹤0.01% 446

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Virtus Fund Advisers's AKCA Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Akcea Therapeutics Inc (AKCA) in Q4 2017: 18,071 shares worth $314K. The stake represents ﹤0.01% of the portfolio and ranks #446 among its holdings.

58 funds tracked by Wall St. Rank hold AKCA as of Q4 2017.

  • Virtus Fund Advisers held 18,071 shares of Akcea Therapeutics Inc worth $314K as of Q4 2017.
  • Akcea Therapeutics Inc was a new Virtus Fund Advisers position in Q4 2017.
  • Akcea Therapeutics Inc made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #446 holding.
  • 58 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.